Market
Veligrotug market entry strategy for TED by end of 2026?
2
Resolution / Starting Odds
Direct sales to healthcare providers • 25%
Partnership with another pharmaceutical company • 25%
Licensing to a third party • 25%
Other strategies • 25%
Viridian Therapeutics announcements or market analysis reports
Story
Viridian Therapeutics' Veligrotug Shows Strong Efficacy in Phase 3 Trial for Thyroid Eye Disease
Dec 16, 2024, 12:26 PM
Viridian Therapeutics Inc. announced positive topline results from its Phase 3 THRIVE-2 clinical trial evaluating veligrotug, an intravenously administered anti-IGF-1R antibody, for the treatment of chronic thyroid eye disease (TED). The trial met all primary and secondary endpoints, showing statistically significant improvements in proptosis, diplopia, and Clinical Activity Scores (CAS) after only five infusions. The study involved 188 patients, with veligrotug demonstrating a 56% proptosis responder rate (PRR) compared to 8% for placebo, and a 56% diplopia response rate against 25% for placebo. The drug was generally well-tolerated, with a 9.6% placebo-adjusted rate of hearing impairment. Viridian is preparing for a Biologics License Application (BLA) submission in the second half of 2025, aiming to offer a differentiated product profile for TED patients. Additionally, the company is advancing its subcutaneous VRDN-003 program, with topline data expected in the first half of 2026.
View original story
Similar markets
Partnership with Non-European Company • 25%
No Market Entry • 25%
Partnership with European Company • 25%
Solo Market Entry • 25%
No significant presence • 25%
Minor market player • 25%
Leading electric aircraft provider • 25%
Significant market player • 25%
Expand to new markets • 25%
Launch new product line • 25%
Acquire another company • 25%
No major strategic move • 25%
Focus on hybrid vehicles • 25%
Other strategies • 25%
Partnerships with European firms • 25%
Establish local manufacturing • 25%
Other • 25%
Direct-to-Consumer • 25%
Business-to-Business • 25%
Licensing Technology • 25%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
Other • 25%
Consumer use • 25%
Commercial use • 25%
Industrial use • 25%
Less than $500 million • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
$500 million to $1 billion • 25%
Defense contracts • 25%
Commercial shipping • 25%
Renewable energy • 25%
Other • 25%
5% to 10% • 25%
Less than 5% • 25%
More than 15% • 25%
10% to 15% • 25%